• Originator Merck Sharp & Dohme
• Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
• Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors

• Orphan Drug Status

  Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  No
• New Molecular Entity Yes

Highest Development Phases

• Discontinued Adenocarcinoma; Biliary cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Haematological malignancies; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cell carcinoma; Small cell lung cancer; Triple negative breast cancer

Most Recent Events

• 05 Aug 2025 Merck Sharp & Dohme completes a phase II trial in Endometrial cancer, Uterine cancer, Head and neck cancer, Gallbladder cancer, Biliary cancer, Endometrial cancer, Oesophageal cancer, Triple-negative-breast cancer, Liver cancer, Ovarian cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Taiwan, Turkey, Spain, Netherlands, Japan, Poland, Netherlands, South Korea, Italy, France, Canada, Canada, USA, Chile, Germany, Israel (IV) (NCT05007106) (EudraCT2021-001009-56)
• 16 Dec 2024 Efficacy and adverse events data from the phase III KeyVibe-003 and phase III KeyVibe-007 trials in Non-small cell lung cancer released by Merck
• 16 Dec 2024 Discontinued - Phase-II for Triple-negative-breast-cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Turkey, Taiwan, Spain, Spain, Poland, Netherlands, South Korea, Japan, Italy, Israel, Germany, France, Chile, Canada, USA (IV)